In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

New Insights on Cardiometabolic Risk Management

CRT Plenary Meeting, 2 half days (afternoon and morning)

24/11/2021 14:00 25/11/2021 12:00 Europe/Paris New Insights on Cardiometabolic Risk Management

Access event page

contact@escardio.org DD/MM/YYYY
In-person
event

Summary

Chairpersons: Prof. Francesco Cosentino (ESC), Dr. Subodh Verma (Toronto), Dr Philip Ambery (AstraZeneca),

Dr Marianne Bach-Treppendahl (Novo Nordisk)

 



Objectives of the meeting

A significant number of patients with cardiovascular disease (CVD) have concomitant metabolic comorbidities which play a causal and/or permissive role in adverse prognosis.

  • The primary objective of the meeting is to improve the recognition and treatment of CVD in patients with multiple metabolic comorbidities. 
  • The meeting also aims to assess potential mechanism-based approaches to intervention across multiple disorders.

Questions to be addressed

  • How can we improve recognition and treatment of cardiovascular disease in patients with obesity, insulin resistance, NASH, and renal disease when associated with metabolic comorbidity?
  • How can we improve the recognition and treatment of metabolic and renal disease in patients at the cardiology clinic?
  • Are there mechanism-based approaches that can address multiple pathologies across diseases?
  • What is important to patients with cardiovascular and metabolic diseases? How can we meet their needs?
  • Why may COVID-19 be particularly damaging for patients with cardiovascular and metabolic disease?
  • Can we move from broad regulatory definitions to better targeting patients with multiple comorbidities?

Programme

 

DAY 1

24 NOVEMBER 2021 – 14:00 – 17:00 CET

14:00 - 14:10

Welcome – Introduction and Objectives of the Workshop                                

Chairpersons

14:10 – 14:40

SESSION 1 - COMMON SOIL AND COMMON TARGETS FOR CKD, NASH, AND HF?

 

The Epidemiological Basis

Prof. Philip Newsome (Birmingham) (TBC)

What are the Biological Underpinnings of the Relationship between Metabolic and Cardiovascular Disease?

Prof. Faiez Zannad (Nancy)

What are the Clinical and Practical Implications for Physicians as it relates to this Interface?

Prof. Per-Henrik Groop (Helsinki)

14:40 – 14:55

Discussion for 15 minutes

14:55 – 15:25

SESSION 2 – UNRAVELLING THE RELATIONSHIPS BETWEEN OBESITY ANDCKD IN

PATIENTS WITH CV DISEASE

 

Epidemiology and Natural history of this Relationship

Prof. Paola Fioretto (Padova)

Obesity and HFpEF – Common Soil?

Prof. Lars Lund (Stockholm)

Obesity Paradox

Prof. Stefan Anker (Berlin)

15:25 – 15:40

Discussion

15:40– 15:50

Break

15:50 – 16:20

SESSION 3 - COVID-19 – A NEW THREAT AT THE CROSSROADS BETWEEN CARDIOVASCULAR AND METABOLIC DISEASES

 

How Metabolic Derangements Affect the Incidence and Natural History of COVID-19

Prof. Naveed Sattar (Glasgow)

CV Derangement in COVID-19

Prof. Scott S. Solomon (Boston) (via videoconference)

What are the Practical Management Implications of Cardiometabolic Disease in Patients with COVID-19

Prof.Kamlesh Khunti (Leicester)

16:20 – 16:35

Discussion

16:35 - 17:00

Panel Discussion and Wrap-up
Let’s continue the conversation tomorrow

 

 

DAY 2

25 NOVEMBER 2021 - 09:00 – 12:00 CET

 09:00 – 09:10

Welcome - Summary of Day 1

Chairpersons

09:10 – 09:40

SESSION 4 - A PATIENT'S PERSPECTIVE ON HEART FAILURE, RENAL DISEASE, AND DIABETES

  • ESC patient
  • Canadian patient

09:40 – 09:55

Discussion

09:55 – 10:25

SESSION 5 - MECHANISMS OF CHRONIC CARDIOMETABOLIC DISEASES AND OPPORTUNITIES FOR INTERVENTION

14:05 - 14:15

Sex Differences in Cardiometabolic Risk and Opportunities for Intervention

Prof. Carolyn Sp Lam (Singapore)

Circulating Biomarkers and their Utility in Cardiometabolic Disease

Prof. Andreas M. Zeiher (Frankfurt)

Altered Bone Marrow Responses?

Prof. David Hess (Toronto)

10:25 – 10:40

Discussion

10:40 – 10:55

Break

10:55 – 11:20

Lecture – Health and Economics Consequences of Obesity
Prof. Michele Cecchini (OECD)

Questions to be addressed

  • What have we learned from the GBD study?
  • What do we need to do to stem the tide?

11:20 - 11:50

Panel Discussion

11.50 - 12.00

Wrap-up – Next steps – A publication